The Faculty of Pharmacy discussed the Master’s Degree thesis,” The Possible Therapeutic Effect of Daflon® diosmin (90%) and (10%) Hesperidin in comparison with Myo-inositol in Letrozole-Induced Poly Cystic Ovary Syndrome Rat Model “by Pary Jameel Saif Allah and his supervisor, Assist. Prof. Dr. Ahmed Hamed Ataimish in Pharmacology and Toxicology Department. The Faculty of Pharmacy discussed the master’s thesis entitled “The Possible Therapeutic Effect of Daflon® diosmin (90%) and (10%) Hesperidin in Comparison with Myo-Inositol in a Letrozole-Induced Poly Cystic Ovary Syndrome Rat Model” This study aimed to evaluate the possible therapeutic effect of Daflon and compare it to myo-inositol in improving poly cystic ovary syndrome induced in rats by evaluating the following parameters: testosterone, luteinizing hormone, follicle stimulating hormone, and the anti-oxidant marker catalase. A vaginal smear was obtained for estrous cycle determination during the experimental period on consecutive days. Body weight was measured weekly during the experimental study to evaluate the treatment’s effect on body weight and for the dose adjustment. An ultrasound examination was carried out for assessing the follicular size at the end of the experiment on all rats. Ovary weights of all rats were measured at the end of the experiment. Histological examination of the rat’s ovary section was also carried out. The results show that Treatment with daflon of high dose (100mg/kg) (DAF_H) was as powerful as Myo-inositol and significantly normalized testosterone level , luteinizing hormone, follicle stimulating hormone and raised the anti-oxidant marker Catalase , it also reduces body and ovary weight , normalized follicular size on ultra sound examination in comparison to the positive control group (p<0.05). The results show that treatment with daflon at a high dose (100mg/kg) (DAF_H) was as effective as Myo-inositol in significantly normalizing testosterone levels, luteinizing hormone, follicle stimulating hormone, and raising the anti-oxidant marker Catalase, as well as reducing body and ovary weight and normalizing follicular size on ultra sound examination (p0.05). While daflon low (50 mg/kg) dose showed a significant (p<0.05) reduction in testosterone and luteinizing hormone compared to the +ve control group, there was no significant difference in follicle stimulating hormone , catalase level, body and ovary weight reduction, or follicle size on ultra sound comparing these results to the +ve control group (p>0.05). Vaginal smear visual observation by microscope showed a faster return to normal cyclicity in DAF_H and myo-inositol groups than DAF_L. Additionally, histological sections of the ovary showed pronounced improvements in ovary sections of DAF_H and Myo-inositol then DAF_L when compared to the +ve control group. These results proved that Daflon-high dose (100mg/kg) was very effective in improving polycystic ovary syndrome and was as beneficial as myo-inositol, while Daflon-low dose (50 mg/kg) only slightly improved the condition.
